BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2026)
BioXcel Therapeutics (BTAI) posted Amortization of Deferred Charges of $774000.0 for Q2 2026, up 54.18% on a QoQ basis from $502000.0 in Q1 2026, and up 96.95% year-over-year from $393000.0 in Q2 2025.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
BioXcel Therapeutics has reported Amortization of Deferred Charges for 5 years, with the latest figure at $774000.0 in Q2 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 96.95% year-over-year to $774000.0 in Q2 2026; TTM through Jun 2026 was $2.2 million, a 104.11% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 253.75% from the prior year.
- Amortization of Deferred Charges was $774000.0 for Q2 2026 at BioXcel Therapeutics, up from $502000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $774000.0 in Q2 2026, with the low at $43000.0 in Q1 2024.
- Average Amortization of Deferred Charges over 5 years is $331117.6, with a median of $333000.0 recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges tumbled 87.09% in 2024, then soared 713.95% in 2025.
- Over 5 years, Amortization of Deferred Charges stood at $322000.0 in 2022, then retreated by 4.66% to $307000.0 in 2023, then fell by 27.69% to $222000.0 in 2024, then jumped by 111.26% to $469000.0 in 2025, then jumped by 65.03% to $774000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $774000.0 (Q2 2026), $502000.0 (Q1 2026), and $469000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 774,000.00 |
| Mar 31, 2026 | 502,000.00 |
| Dec 31, 2025 | 469,000.00 |
| Sep 30, 2025 | 441,000.00 |
| Jun 30, 2025 | 393,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Sep 30, 2023 | 377,000.00 |
| Jun 30, 2023 | 356,000.00 |
| Mar 31, 2023 | 333,000.00 |
| Dec 31, 2022 | 322,000.00 |
| Sep 30, 2022 | 217,000.00 |
| Jun 30, 2022 | 321,000.00 |